35 research outputs found
Bioactivity of aqueous extracts of Clibadium sylvestre (Aubl.) Baill. and Derris amazonica Killip on the aphid Myzus persicae (Sulzer, 1776) (Hemiptera: Aphididae)
Genealogies of the colonial present: the rediscovery of the local in conflict management interventions in Mindanao, the Southern Philippines
Use of totally implantable central venous access port via the basilic vein in patients with thoracic malignancies
Initiation of Chemotherapy in Cancer Patients with Poor Performance Status: A Population-Based Analysis
Prognostic factors in de novo metastatic renal cell carcinoma : A report from the latin american renal cancer group
Altres ajuts: Janssen Biotech, Merck, Pharmacyclics, Incyte, Taiho Pharmaceutical.PURPOSE To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries. PATIENTS AND METHODS Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 2015, a total of 530 (14.5%) had metastasis at clinical presentation. Relationships between clinical and pathological parameters and treatment-related outcomes were analyzed by Cox regression and the log-rank method. RESULTS Of 530 patients, 184 (90.6%) had died of renal cell carcinoma. The median OS of the entire cohort was 24 months. American Society of Anesthesiology classification 3-4 (hazard ratio [HR]: 1.64), perirenal fat invasion (HR: 2.02), and ≥ 2 metastatic organ sites (HR: 2.19) were independent prognostic factors for 5-year OS in multivariable analyses. We created a risk group stratification with these variables: no adverse risk factors (favorable group), median OS not reached; one adverse factor (intermediate group), median OS 33 months (HR: 2.04); and two or three adverse factors (poor risk group), median OS 14 months (HR: 3.58). CONCLUSION Our study defines novel prognostic factors that are relevant to a Latin American cohort. With external validation, these easily discerned clinical variables can be used to offer prognostic information across low- and middle-income countries